Video Programs

Panelists discuss how chronic graft-versus-host disease manifests across multiple organ systems and the diagnostic criteria used to identify and assess its various presentations.

Dr Sekeres discusses when to start therapy for a patient who has lower-risk MDS with amnesia.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with imetelstat.

Dr Sekeres discusses treatment goals for a patient with lower-risk MDS.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.

Dr Sekeres discusses key takeaways for optimizing anemia management in lower-risk MDS, as well as where he sees the most significant unmet needs.

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with lenalidomide.

Dr Sekeres shares his thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.

Dr Sekeres discusses the adverse event profile and AE management of imetelstat.

Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.

The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.

Mikkael Sekeres, MD details a clinical presentation of a 74-year-old man diagnosed 9 months ago with LR-MDS with a hemoglobin of 7.8 g/dL.

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.

Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.

Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.

The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.

Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.

Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.